Jacob Lee Houghton

Title: Jacob Lee Houghton: Innovator in Radioligand Imaging

Introduction

Jacob Lee Houghton is a prominent inventor based in New York, NY (US). He has made significant contributions to the field of medical imaging, particularly in the development of radioligands for pretargeted PET imaging. His innovative work aims to enhance cancer detection and treatment methodologies.

Latest Patents

Houghton holds a patent titled "Radioligands for pretargeted PET imaging and methods of their therapeutic use." This patent describes Tz/TCO-based pretargeting strategies utilizing an Al[F]-NOTA-labeled tetrazine radioligand. This imaging strategy allows for the delineation of cancer at earlier time points compared to other imaging techniques. Additionally, it reduces the radiation dose to healthy tissues when compared to directly labeled antibodies. The achievement of Al-based F imaging of small molecules, such as tetrazine, is noteworthy, as it had not been accomplished previously due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because it has a shorter half-life and is more readily available for integration into hospital workflows.

Career Highlights

Jacob Lee Houghton is affiliated with the Memorial Sloan Kettering Cancer Center, where he continues to advance his research and innovations in the field of cancer imaging. His work is pivotal in improving patient outcomes through enhanced imaging techniques.

Collaborations

Houghton collaborates with esteemed colleagues, including Brian Zeglis and Jason S. Lewis, who contribute to the research and development of innovative imaging strategies.

Conclusion

Jacob Lee Houghton is a key figure in the advancement of radioligand imaging, with a focus on improving cancer detection and treatment. His contributions are vital to the ongoing evolution of medical imaging technologies.